MAVENIR
27.5.2021 15:02:13 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, has announced support for deployments and integration of cloud-native telecom network functions with telco infrastructure solutions on Amazon Web Services, Inc. (AWS).
Mavenir’s collaboration with AWS allows Communications Service Providers (CSPs) to deploy Mavenir’s market leading 4G and 5G products and applications with AWS’s computing infrastructure, state of the art container deployment and management technologies, and big data analytics services. The solution is designed to scale and leverages the same tools and technologies offered by AWS to enterprise applications today. These tools are the backbone for visibility and automation for any AWS-based offering and generally referred to as Platform-as-a-Service (PaaS). This translates to offloading some of the telco application business to cloud functions, reducing complexity and putting service providers at par with organizations enjoying cost savings from cloud migrations without losing insight, performance, and control on their networks.
Another key element from this collaboration is the enablement of Private Networks and Edge deployments on AWS, powered by Mavenir’s Digital Enablement platform . With a digital app store for enterprise and various industry 4.0 applications such as IVA, AR/VR, IIoT and Robotics control, Mavenir’s Edge AI application suite is empowering an ecosystem of developers, service providers, partners, and enterprises to create and deploy applications in AWS to power digitalization and industry 4.0 with 5G.
This collaboration also lowers the network deployment time and cost for MNOs and enterprises equally fulfilling use cases of either adding 5G and edge capabilities to an existing network or a greenfield 4G/5G network launch leveraging public clouds.
“The collaboration with Mavenir and AWS allows us to build out our 5G network and messaging platforms in a true cloud-native manner, harnessing the speed and agility that the AWS cloud brings along with Mavenir’s expertise in deploying and operating cloud-native network functions," said Sidd Chenumolu, Vice President of Technology Development, DISH. “Together, we will enable our customers to take full advantage of the potential of 5G, reimagining wireless connectivity and giving our customers the ability to customize their network experience.”
“Working with AWS enables us to bring new customer-focused 5G use cases and 5G deployments to the market faster and with unique capabilities to realize true 5G potential,” said Bejoy Pankajakshan, Mavenir’s Chief Strategy Officer. “Mavenir’s solutions are designed to support full public cloud as well as hybrid cloud deployments.”
"We’re delighted to collaborate with Mavenir to offer voice and messaging solutions for core network and RAN customers along with AI/ML solutions for orchestration and observability,” said Amir Rao, General Manager Telco Solution Portfolio and Tech Alliances, AWS. “Together, we are providing true cloud native benefits to CSP customers, combining Mavenir’s expertise in the NFV market with the global scale of the AWS infrastructure to meet industry challenges of agility, scaling, slicing, and resiliency.”
Mavenir’s 4G and 5G deployments on AWS provides unique capabilities, including:
- Integration of Mavenir’s cloud-native Open RAN (vDU, vCU-CP, vCU-UP), Converged 4G/5G Packet Core, IMS, and Messaging with Amazon Elastic Kubernetes Service (Amazon EKS) anywhere supporting AWS Outposts.
- Use of AWS platform services and tools to deploy and manage cloud native network functions.
- Options for existing deployments to migrate Mavenir’s IMS core, voice, and messaging solutions to Amazon EKS and Amazon Elastic Compute Cloud (Amazon EC2) infrastructure.
- Mavenir’s Orchestration and Network Slicing solutions to manage hybrid cloud workloads running on AWS.
- Adoption of AWS for centrally managed telco workloads on far-edge, network edge and core simultaneously.
- Deployment of Mavenir’s standards compliant observability framework, RIC, NWDAF, AIOps and Analytics platform in AWS to collect the data from various AWS nodes in a centrally managed data lake and process the data using AI/ML for network wide insights and optimization.
- Integration of Mavenir’s telecom adaptation layer (Telco PaaS) as a common open source-based platform adaptation layer designed for telco specific workloads to support various carrier grade requirements on top of Amazon EKS and AWS PaaS functions.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Visit: www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005102/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom